Long Ideas - Achillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article on ACHN here), as the hepatitis C (HCV) space continues … Continue Reading
Read nowLong Ideas - Shares of Navidia Biopharmaceuticals (NASDAQ:NAVB) could trade higher today following a positive update from the company last night regarding the potential approval of lead product … Continue Reading
Read nowLong Ideas - SciClone Pharmaceuticals (NASDAQ:SCLN) started the day strong, as the company is being cited by dealReporter as exploring strategic options. According to sources, the publication is noting … Continue Reading
Read nowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) and ViroPharma (NASDAQ:VPHM) announced this morning that the FDA is enabling their subcutaneous version (SC) of Cinryze, a treatment for hereditary angioedema … Continue Reading
Read nowLong Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) released in an 8-k Thursday night that it has entered into an agreement with Ironwood Pharmaceuticals (NASDAQ:IRWD) for an exclusive worldwide license … Continue Reading
Read nowResearch - The 48% decline seen for shares of Questcor Pharmaceuticals (NASDAQ:QCOR) Wednesday prompts the key question of: What to do with the stock now? As a … Continue Reading
Read nowLong Ideas - After Bristol-Myers Squibb (NYSE:BMY) discontinued development of BMS-986094, once a promising nucleotide type drug for hepatitis C (HCV), in August, funds invested in this drug … Continue Reading
Read now